After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

我们距离修复一切遗传性疾病更近了一步。 在生物医学领域，被称为“基因剪刀”的CRISPR基因编辑技术一直备受关注，用它修复一切遗传性疾病更是愿景。 近日，全球首例个性化CRISPR基因编辑疗法成功应用于一名患有罕见遗传性疾病的婴儿，为单个患者量身定制基因编辑疗法，让我们离上述愿景更近了一步。 该案例5月15日发表在了《新英格兰医学杂志》（NEJM）上。 这名婴儿叫KJ，他患有严重的代谢疾病——氨甲 ...

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand treatment to others.

Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiationSAN FRANCISCO and BERLIN, ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its financial results for 2025, highlighting a period of significant commercial ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...

CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private ...